Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed-dose OPC-34712 in the Treatment of Adults With Acute Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms BEACON
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 01 Mar 2022 Results evaluating the short- and long-term effects of brexpiprazole on patient functioning in schizophrenia using post hoc analysis of short and long term studies published in the Journal of Clinical Psychiatry
- 15 Sep 2020 Results of post hoc analysis assessing effect of brexpiprazole on patient engagement in patients with schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 23 Oct 2019 Results of post hoc analysis of data from two 6-week, randomized, double-blind, placebo-controlled studies (ClinicalTrials.gov identifiers, NCT01396421 and NCT01393613) and a 52-week, open-label, extension study (NCT01397786) assessing the short and long term efficacy of brexpiprazole for reducing agitation and hostility in schizophrenia published in the Journal of Clinical Psychopharmacology